<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04385082</url>
  </required_header>
  <id_info>
    <org_study_id>19-000876</org_study_id>
    <nct_id>NCT04385082</nct_id>
  </id_info>
  <brief_title>Cannabis Effects as a Function of Sex (CanSex)</brief_title>
  <acronym>CanSex</acronym>
  <official_title>Sex-dependent Effects of Cannabis: Assessing Analgesic, Abuse-related and Pharmacokinetic Differences Between Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to assess the impact of cannabis on the analgesic and
      abuse-related effects between men and women
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will compare smoked cannabis's dose-dependent, analgesic and abuse-related
      effects between men and women and variables that underlie these sex-dependent differences,
      including pharmacokinetics of THC.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a randomized, double-blind, placebo-controlled study. All participants will complete all dose conditions in a randomized order.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject-rated drug effects</measure>
    <time_frame>5 hours</time_frame>
    <description>Average and peak subjective ratings of drug effects associated with abuse liability as measured using visual analogue scales (VAS; 1-100mm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analgesia as measured using the Cold Pressor Test</measure>
    <time_frame>5 hours</time_frame>
    <description>Peak and average pain threshold and tolerance assessed using the Cold Pressor Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of THC and metabolites</measure>
    <time_frame>5 hours</time_frame>
    <description>Plasma levels of THC, 11-OH-THC, and THCCOOH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug reinforcement</measure>
    <time_frame>5 hours</time_frame>
    <description>Cannabis self-administration task: number of cannabis puffs self-administered per session</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Pain</condition>
  <condition>Abuse, Drug</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Smoked Cannabis (~0% THC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low strength cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked Cannabis (~4% THC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher strength cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked Cannabis (~10% THC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Cannabis</intervention_name>
    <description>Smoked cannabis with THC</description>
    <arm_group_label>Higher strength cannabis</arm_group_label>
    <arm_group_label>Low strength cannabis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Cannabis</intervention_name>
    <description>Placebo smoked cannabis (no THC)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant female aged 21-55 years

          -  Report use of cannabis an average of 1-7 days per week

          -  Not currently seeking treatment for their cannabis use

          -  Urine test positive for recent cannabis use for heavy users

          -  No reported adverse effects with cannabis smoking in light users

          -  Have a Body Mass Index from 18.5 - 34kg/m2.

          -  Able to perform all study procedures

          -  FEMALES: Currently practicing a non-hormonal effective form of birth control

          -  FEMALES: Must be regularly cycling

        Exclusion Criteria:

          -  Meeting DSM-V criteria for any substance use disorder other than nicotine, caffeine,
             or cannabis use disorder

          -  Report using other illicit drugs in the prior 4 weeks

          -  History or current evidence of severe psychiatric illness or medical condition judged
             by the study physician and PI to put the participant at greater risk of experiencing
             adverse events due to completion of study procedures, interfere with their ability to
             participate in the study, or their capacity to provide informed consent.

          -  Current use of medical cannabis, prescription analgesics, or any medications that may
             affect study outcomes

          -  Current pain

          -  Insensitivity to the cold water stimulus of the Cold Pressor Test

          -  FEMALES: using a hormonal contraceptive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziva Cooper, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ziva Cooper, PhD</last_name>
    <phone>310-206-9942</phone>
    <email>zcooper@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vincent Acebo</last_name>
    <phone>310-983-3417</phone>
    <email>vacebo@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ziva Cooper, Phd</last_name>
      <phone>310-206-9942</phone>
      <email>zcooper@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vincent Acebo</last_name>
      <phone>310-983-3417</phone>
      <email>vacebo@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ziva Cooper, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Ziva D. Cooper, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Cannabis</keyword>
  <keyword>THC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

